These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 26220911

  • 1. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED.
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [Abstract] [Full Text] [Related]

  • 2. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

  • 3. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 5. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [Abstract] [Full Text] [Related]

  • 6. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [Abstract] [Full Text] [Related]

  • 7. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S, Kavanaugh A.
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J.
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [Abstract] [Full Text] [Related]

  • 12. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L.
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [Abstract] [Full Text] [Related]

  • 13. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ.
    Arthritis Res Ther; 2019 May 10; 21(1):118. PubMed ID: 31077258
    [Abstract] [Full Text] [Related]

  • 14. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.
    Ann Rheum Dis; 2014 Jun 10; 73(6):1020-6. PubMed ID: 24595547
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar 10; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB.
    Br J Dermatol; 2015 Dec 10; 173(6):1387-99. PubMed ID: 26357944
    [Abstract] [Full Text] [Related]

  • 17. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G, Campanati A, Diotallevi F, Molinelli E, Offidani A.
    G Ital Dermatol Venereol; 2019 Apr 10; 154(2):166-169. PubMed ID: 30229640
    [Abstract] [Full Text] [Related]

  • 18. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
    Abdulrahim H, Thistleton S, Adebajo AO, Shaw T, Edwards C, Wells A.
    Expert Opin Pharmacother; 2015 May 10; 16(7):1099-108. PubMed ID: 25864487
    [Abstract] [Full Text] [Related]

  • 19. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC, McNamee KE, McCann FE.
    Drug Des Devel Ther; 2013 May 10; 7():201-10. PubMed ID: 23569359
    [Abstract] [Full Text] [Related]

  • 20. Apremilast for the treatment of psoriatic arthritis.
    Souto A, Gómez-Reino JJ.
    Expert Rev Clin Immunol; 2015 May 10; 11(12):1281-90. PubMed ID: 26503917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.